Implementing a safe opioid taper for hospital inpatients

Opioid prescribing during an admission can relieve severe pain, but an inherited dose is not automatically appropriate for the current illness. A safe protocol must distinguish acute pain from long-term opioid therapy, recognise non-opioid contributors, and define when reduction is justified. It must protect against withdrawal, uncontrolled pain, sedation and overdose after tolerance falls. The task is not simply to lower a number on the medication chart; it is to maintain comfort, safety and trust while correcting a risky regimen.

Hospital Medicine 2017, held from 1 to 4 May at Mandalay Bay in Las Vegas, brought hospitalists together for research, practical education and continuing professional development. Its conference education resources remain useful for teams turning recommendations into daily workflows. The legacy for an Australian ward is not to copy an American protocol verbatim, but to retain its discipline: define the indication, quantify exposure, involve the patient, monitor outcomes and arrange follow-up before discharge.

This framework addresses how to implement a safe opioid tapering protocol for inpatients and turns the HM17 plan into a locally governed pathway. It applies to adults in public and private hospitals across Sydney, Melbourne, Brisbane, Perth and regional centres, while state formularies, specialist services and pharmacy arrangements differ. Australian prescribing customs include the Pharmaceutical Benefits Scheme, PBS-listed products and the Australian Register of Therapeutic Goods. Clinicians should also account for over-the-counter codeine, sedating medicines, illicit opioid use and medicines obtained from informal markets.

Establish why the opioid is being used

Begin with medication reconciliation rather than a taper percentage. Confirm the exact medicine, formulation, strength, dose, duration, indication, prescriber and adverse effects. Ask what the patient expects the opioid to achieve, what happens when a dose is missed and whether another clinician has attempted a reduction. Electronic medication records, pharmacy reviews and My Health Record can expose discrepancies in Australian hospitals, but missing information still requires conversation with the patient, family, community pharmacist and usual general practitioner.

Then examine the clinical indication. Cancer-related pain, palliative care, acute postoperative pain and persistent non-cancer pain require different goals. Do not taper opioid therapy used for active palliative care or unstable acute pain. For persistent pain, assess whether the original diagnosis remains valid and whether benefits still exceed harms. Review function, sleep, mood, bowel symptoms, falls, work or caregiving responsibilities, and non-opioid options that were never tried. Pain score alone should not determine a reduction.

Assess risk before changing the regimen. Tolerance, renal or hepatic impairment, sleep apnoea, pregnancy, frailty and concurrent benzodiazepines or alcohol magnify the consequences of the existing dose and a rapid reduction. Document the reason for any high daily dose and exclude duplicate prescriptions. If addiction rather than physical dependence is suspected, involve addiction medicine or an alcohol and other drug service without withholding acute care. Treat methadone and buprenorphine for opioid use disorder as specialist treatments, not routine taper candidates. For Aboriginal and Torres Strait Islander patients, use Aboriginal health teams and culturally safe communication rather than assumptions about pain, family responsibility or substance use.

Agree on a patient-centred taper

Use shared decision-making to set goals: stable pain, reduced sedation, fewer falls, safer breathing, better bowel function, or cessation of an unneeded medicine. Explain that physical dependence is expected after prolonged use and that withdrawal does not mean pain is returning or treatment has failed. Offer written information, interpreters and time for questions. Patients with impaired capacity still require assent where possible, proxy participation and a best-interest assessment.

Choose the pace from exposure, preferences and clinical stability. For long-term opioid therapy, many Australian deprescribing services begin with roughly 5–10% off the current dose, often monthly or slower, then wait to assess withdrawal, pain and function. A short, closely monitored inpatient trial may be appropriate when the indication is uncertain, but should not trigger an aggressive schedule merely to create a measurable discharge dose. Frail patients and those with severe withdrawal need slower reductions.

Build in checkpoints and pause rules. Write down the current dose, next dose, review date, responsible clinician and what to do if pain or withdrawal worsens. The Clinical Opiate Withdrawal Scale, or COWS, can improve consistency, although scores should support, not replace, clinical judgement. If pain is stable and withdrawal is not significant, continue the agreed reduction. If symptoms are severe, the patient is unstable or a new diagnosis explains the original pain, pause or slow the taper. Avoid abrupt discontinuation unless the opioid causes immediate life-threatening toxicity; even then, provide a structured withdrawal and pain plan.

Make the protocol executable on the ward

A taper works only if every shift understands it. Place the indication, target, schedule, monitoring requirements and rescue plan in the medication record and prominent handover notes. Do not use “opioid reduction” without a dose and date; ambiguity invites accidental restarting. Prescribers should review the plan daily, and nurses should be empowered to report worsening symptoms before the next reduction.

Use “start, hold and reassess” language for the first prescription decision. Start only the indicated dose; hold a usual opioid if the patient is sedated, the respiratory rate is reduced, the indication has resolved or an acute deterioration is suspected. Record the reason so a hold is not mistaken for non-adherence. If fever or systemic illness develops, reassess rather than automatically attributing symptoms to withdrawal; the related approach to persistent fever offers a useful model for preserving diagnostic uncertainty while managing care. When converting formulations, calculate by the prescribed opioid rather than milligram morphine alone because equianalgesic estimates vary and can mislead in renal or hepatic impairment.

Coordination extends beyond the ward. Include the treating team, pharmacist, pain or palliative care service, addiction medicine where relevant, and the community clinician who will take over. Check access to take-home naloxone, oral liquids, patches and opioid alternatives because stock differs between metropolitan and regional services; Australian community pharmacies can supply naloxone without a prescription. The local market includes PBS-listed oxycodone and hydromorphone products and buprenorphine formulations, but availability and subsidy are not uniform. A prescription that cannot be dispensed is not a safe discharge plan.

Anticipate withdrawal, relapse and inequitable harm

Explain likely withdrawal: yawning, sweating, rhinorrhoea, abdominal cramps, diarrhoea, restlessness, tremor, anxiety and insomnia may emerge over hours to days depending on the opioid. Severe symptoms need treatment, not confrontation. Symptomatic options may include antiemetics, antidiarrhoeals, clonidine where appropriate and specialist advice. Avoid increasing the taper when withdrawal appears; pause the schedule, relieve symptoms and revisit the plan.

Reduced tolerance increases overdose risk if the patient returns to a former dose. Provide take-home naloxone and train a family member or carer when appropriate. Teach safe storage and disposal, including returning unused medicines to a participating pharmacy. After discharge, arrange review with the usual general practitioner or an opioid management service within a week, and avoid open-ended repeats that permit overlapping prescriptions. Where illicit opioids are involved, offer harm reduction without making tapering a condition of care.

Equity must be tested rather than assumed. People who use interpreters, have disability, live with chronic illness or rely on public transport may need more time, accessible instructions and closer follow-up. In major cities, fragmented after-hours services can complicate escalation; in rural and remote locations, distance, limited pharmacy stock and service closures can make a written taper insufficient. Build escalation contacts, remote review options and contingency supplies into the pathway. Respect family and community support while avoiding assumptions about who should control the medicine.

Operationalise, audit and sustain the pathway

Pilot the protocol on one ward with a multidisciplinary owner in each discipline. Use a standard order set or electronic template supported by a patient handout and discharge checklist. Teach staff to distinguish withdrawal from recurrent disease, document a hold and respond when a patient declines further reduction. A protocol that removes a prescription but leaves pain untreated will fail, even if the medication chart looks tidier.

Audit processes and outcomes separately. Measures include documentation of indication and duration, shared decision-making, unplanned withdrawal, falls or delirium after reduction, naloxone provision, timely follow-up and patient-reported pain and function. Do not reward teams for tapering speed; a low reduction rate can reflect appropriate caution. Review unexpected events and feedback from Aboriginal health teams, consumers and pharmacy services, then revise the pathway. Archived HM17 material can support education, but current Australian guidance and local governance should determine the standard of care.

The following comparison helps teams select the safest response to each clinical situation; the percentages are starting points, not mandates.

A practical ward rule is simple: every opioid order should state why it is needed, what happens next and who will review it. For a stable patient ready to reduce, start with a small agreed change, document the response and make the next step explicit. Before discharge, confirm that the taper is understood, the supply is obtainable and follow-up is booked; that combination turns an individual order into a safe, continuous protocol.